K. A. Gelmon, M. Tischkowitz, H. Mackay, K. Swenerton, A. Robidoux, K. Tonkin, H. Hirte, D. Huntsman, M. Clemons, B. Gilks, R. Yerushalmi, E. Macpherson, J. Carmichael and A. Oza, “Olaparib in Patients with Recurrent High-Grade Serous or Poorly Differentiated Ovarian Carcinoma or Triple-Negative Breast Cancer: A Phase 2, Multicentre, Open-Label, Non-Randomised Study,” The Lancet Oncology, Vol. 12, No. 9, 2011, pp. 852-861. doi:10.1016/S1470-2045(11)70214-5

has been cited by the following article:

• TITLE: Case Report: Complete Clinical Response of a Young Patient with a BRCA 2 Positive Metastatic Breast Cancer

  AUTHORS: Grazia Artioli, Giuseppe Azzarello, Fabrizio Meggiolaro, Jacopo Wabersich, Lucia Borgato, Mario Bari

  KEYWORDS: BRCA 2; Breast Cancer; DNA; Cisplatin; Taxane

  JOURNAL NAME: Advances in Breast Cancer Research, Vol.2 No.3, June 24, 2013

  ABSTRACT: Background: Metastatic breast cancer in BRCA 2 patients is lacking of target therapy studies. Case: We present a case of a 34-year-old woman affected by a recurrent metastatic breast cancer after 5 years treated with weekly nab-paclitaxel and three weekly Cisplatin obtaining a radiological complete response with 6 cycles. Conclusion: It is important to emphasize that patients with a molecular disorder who selected for “target” chemotherapy can obtain optimal response rate. Exploiting the mechanism of action of DNA damage in our favor, using cisplatin for example and basing on literature show the efficacy of using taxane in BRCA 2 patients, obtaining a very high response rate.